Immunomodulators in the treatment of asthma

Allergy and Asthma Proceedings

Volumn 30, Issue 2, 2009, Pages 109-119

  Long, Aidan A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Airway inflammation; Asthma; Cytokine blockers; Dendritic cell; IgE; Immunomodulators; Monoclonal antibodies; Omalizumab; T H2 cells; TH1 cells

Indexed keywords

ADALIMUMAB; ALTRAKINCEPT; CORTICOSTEROID DERIVATIVE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 25; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 9; MEDI 528; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PASCOLIZUMAB; PITAKINRA; PLACEBO; PROTEIN KINASE SYK INHIBITOR; RECOMBINANT INTERLEUKIN 12; REZLIZUMAB; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; IMMUNOLOGIC FACTOR;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ANGIONEUROTIC EDEMA; ASPERGILLOMA; ASTHMA; ATOPIC DERMATITIS; CELL ACTIVATION; CHRONIC URTICARIA; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG TARGETING; EOSINOPHILIC ESOPHAGITIS; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOMODULATION; LIVER FUNCTION TEST; MAST CELL; NONHUMAN; PHENOTYPE; RHINOCONJUNCTIVITIS; SIDE EFFECT; SINGLE DRUG DOSE; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; DRUG APPROVAL; DRUG DESIGN; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG APPROVAL; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; UNITED STATES;

EID: 67650434286     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3203     Document Type: Conference Paper

References (75)

1. Pascual RM, and Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 116:477-486, quiz 487, 2005.
2. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 344:350-362, 2001.
3. Galli SJ, Tsai M, and Piliponsky AM. The development of allergic inflammation. Nature 454:445-454, 2008.
4. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int 57:1-10, 2008.
5. Schleimer RP, Kato A, Kern R, et al. Epithelium: At the interface of innate and adaptive immune responses. J Allergy Clin Immunol 120:1279-1284, 2007.
6. Lambrecht BN. Lung dendritic cells: Targets for therapy in allergic disease. Curr Mol Med 8:393-400, 2008.
7. Maurer D, Ebner C, Reininger B, et al. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol 154:6285-6290, 1995.
8. Maurer D, Ebner C, Reininger B, et al. Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells. Adv Exp Med Biol 417:175-178, 1997.
9. Holt PG, and Upham JW. The role of dendritic cells in asthma. Curr Opin Allergy Clin Immunol 4:39-44, 2004.
10. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5:471-484, 2006.
11. Bhattacharjee RN, and Akira S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 6:287-291, 2006.
12. Hayashi T, and Raz E. TLR9-based immunotherapy for allergic disease. Am J Med 119:897, e1-6, 2006.
13. Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 4:283-288, 2007.
14. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355:1445-1455, 2006.
15. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 113:235-241, 2004.
16. Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113:1144-1151, 2004.
17. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673-680, 2002.
18. Gilliet M, Soumelis V, Watanabe N, et al. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. J Exp Med 197:1059-1063, 2003.
19. Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204:253-258, 2007.
20. Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37:2779-2786, 2007.
21. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1-family member IL-33. Blood 113:1526-1539, 2009.
22. Nakajima H, and Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 142:265-273, 2007.
23. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 107:963-970, 2001.
24. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160:1816-1823, 1999.
25. Adcock IM, Caramori G, and Chung KF. New targets for drug development in asthma. Lancet 372:1073-1087, 2008.
26. Andrews AL, Holloway JW, Holgate ST, and Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol 176:7456-7461, 2006.
27. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 130:93-100, 2002.
28. Rothenberg ME, and Hogan SP. The eosinophil. Annu Rev Immunol 24:147-174, 2006.
29. Doherty T, and Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 19:676-680, 2007.
30. Dent LA, Strath M, Mellor AL, and Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 172:1425-1431, 1990.
31. Lee JJ, McGarry MP, Farmer SC, et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 185:2143-2156, 1997.
32. Akutsu I, Kojima T, Kariyone A, et al. Antibody against interleukin-5 prevents antigen-induced eosinophil infiltration and bronchial hyperreactivity in the guinea pig airways. Immunol Lett 45:109-116, 1995.
33. Van Oosterhout AJ, Ladenius AR, Savelkoul HF, et al. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 147:548-552, 1993.
34. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356:2144-2148, 2000.
35. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med 167:1655-1659, 2003.
36. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176:1062-1071, 2007.
37. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029-1036, 2003.
38. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 169:6459-6466, 2002.
39. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 169:6452-6458, 2002.
40. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2334-2339, 2003.
41. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113:115-119, 2004.
42. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103:2939-2941, 2004.
43. Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118:1312-1319, 2006.
44. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358:1215-1228, 2008.
45. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 202:175-190, 2004.
46. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: Central mediator of allergic asthma. Science 282:2258-2261, 1998.
47. Wynn TA. IL-13 effector functions. Annu Rev Immunol 21:425-456, 2003.
48. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263, 1998.
49. Yang G, Volk A, Petley T, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28:224-232, 2004.
50. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 370:1422-1431, 2007.
51. Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2149-2153, 2000.
52. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132, 2005.
53. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 38:2636-2649, 2008.
54. Wang YH, and Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol 20:697-702, 2008.
55. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 181:4089-4097, 2008.
56. Ballantyne SJ, Barlow JL, Jolin HE, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 120:1324-1331, 2007.
57. Wang YH, Angkasekwinai P, Lu N, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 204:1837-1847, 2007.
58. Kambayashi T, and Koretzky GA. Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J Allergy Clin Immunol 119:544-552, quiz 553-554, 2007.
59. Guyer BJ, Shimamoto SR, Bradhurst AL, et al. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc 27:208-213, 2006.
60. Meltzer EO, Berkowitz RB, and Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 115:791-796, 2005.
61. Hirasawa N, Scharenberg A, Yamamura H, et al. A requirement for Syk in the activation of the microtubule-associated protein kinase/phospholipase A2 pathway by Fc epsilon R1 is not shared by a G protein-coupled receptor. J Biol Chem 270:10960-10967, 1995.
62. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:1828-1834, 1997.
63. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593, 2004.
64. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-190, 2001.
65. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261, 2001.
66. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302-308, 2005.
67. Corren J, Casale T, Deniz Y, and Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthmarelated emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 111:87-90, 2003.
68. Moore WC, and Peters SP. Severe asthma: An overview. J Allergy Clin Immunol 117:487-494, 2006.
69. Brightling C, Berry M, and Amrani Y. Targeting TNF-alpha: A novel therapeutic approach for asthma. J Allergy Clin Immunol 121:5-10, quiz 11-2, 2008.
70. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60:1012-1018, 2005.
71. Thomas PS, and Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57:774-778, 2002.
72. Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: Markers of systemic inflammation? Clin Exp Allergy 36:1373-1381, 2006.
73. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354(7):697-708, 2006.
74. Morjaria J, Chauhan A, Bobu K, et al. Assessment of a soluble TNFalpha fusion protein (etanercept) as a novel therapeutic agent for severe refractory asthma. Proc Am Thorac Soc 3:A16, 2006.
75. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174:753-762, 2006.